biote: 3 Key Takeaways for Long-Term Investors
On its third-quarter 2026 earnings call, held on Nov. 4, 2026, biote (NASDAQ:BTMD) announced full-year 2026 revenue guidance above $175 million despite a 9.6% year-over-year quarterly revenue decline to $43.3 million. Revenue contracted after a January 2026 voluntary product recall delayed new clinic onboarding and clinical procedure volume. Three takeaways from the call stand out for long-term investors. Management is deploying data analytics to identify clinics needing operational support and to enforce sales team accountability. Directing field representatives toward lagging practices aims to reduce clinic attrition and rebuild procedure volume. Continue reading